Cretostimogene Cuts NMIBC Recurrence 68% in Phase 3; FDA Rejects Ivonescimab
Cretostimogene cut NMIBC recurrence risk 68% (HR 0.32) in Phase 3, Lexeo's LX2020 posted strong interim data, while Summit took an FDA CRL and Aclaris missed Phase 2 in atopic dermatitis.
